These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19903356)

  • 41. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors.
    Ou WB; Zhu MJ; Demetri GD; Fletcher CD; Fletcher JA
    Oncogene; 2008 Sep; 27(42):5624-34. PubMed ID: 18521081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. C-kit, GIST, and imatinib.
    Siehl J; Thiel E
    Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.
    Consolino L; Longo DL; Sciortino M; Dastrù W; Cabodi S; Giovenzana GB; Aime S
    Gastric Cancer; 2017 Jul; 20(4):629-639. PubMed ID: 27995483
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
    Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
    García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
    Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High CD133 expression levels in gastrointestinal stromal tumors.
    Bozzi F; Conca E; Manenti G; Negri T; Brich S; Gronchi A; Pierotti MA; Tamborini E; Pilotti S
    Cytometry B Clin Cytom; 2011; 80(4):238-47. PubMed ID: 21462307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors.
    Hsu KH; Tsai HW; Lin PW; Hsu YS; Lu PJ; Shan YS
    World J Surg Oncol; 2014 Jun; 12():189. PubMed ID: 24947165
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib.
    Cassier PA; Dufresne A; Arifi S; El Sayadi H; Ray-Coquard I; Bringuier PP; Scoazec JY; Alberti L; Blay JY
    Curr Gastroenterol Rep; 2008 Dec; 10(6):555-61. PubMed ID: 19006610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
    Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S
    Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Expression of MDR1 and KIT in imatinib-resistant gastrointestinal stromal tumor cells].
    Liu JL; Qin J; Yao LQ; Hou YY; Sun YH; Shen KT; Su P
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Jul; 13(7):506-9. PubMed ID: 20658364
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imatinib mesylate induces responses in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy.
    Fiorentini G; Bernardeschi P; Rossi S; Dentico P; Biancalani M; Giustarini G; Turrisi G
    J Cancer Res Ther; 2006; 2(2):68-71. PubMed ID: 17998678
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.
    Yeh CN; Chen TW; Liu FY; Jan YY; Chen MF
    Langenbecks Arch Surg; 2006 Nov; 391(6):615-21. PubMed ID: 17024483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Imatinib resistance in gastrointestinal stromal tumors.
    Chen LL; Sabripour M; Andtbacka RH; Patel SR; Feig BW; Macapinlac HA; Choi H; Wu EF; Frazier ML; Benjamin RS
    Curr Oncol Rep; 2005 Jul; 7(4):293-9. PubMed ID: 15946589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
    Apice G; Milano A; Bruni GS; Iaffaioli RV; Caponigro F
    Rev Recent Clin Trials; 2006 Jan; 1(1):35-42. PubMed ID: 18393778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
    Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
    Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
    Demetri GD
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.
    Cullinane C; Dorow DS; Kansara M; Conus N; Binns D; Hicks RJ; Ashman LK; McArthur GA; Thomas DM
    Cancer Res; 2005 Nov; 65(21):9633-6. PubMed ID: 16266981
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.